Revenue
2021
2022
2023
2024
2025
Krystal Biotech, Inc. (KRYS)
Price—Loading quote
Net income
2017
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 | — | — | — | — |
| Research & development | $58.0M | $53.6M | $46.4M | $42.5M | $27.9M | $17.9M | $15.6M | $3.2M | $741,000 |
| Operating expenses | $227.8M | $224.8M | $160.3M | $145.2M | $68.3M | $33.0M | $22.1M | $4.8M | $1.1M |
| Operating income | $161.3M | $65.7M | −$109.6M | −$145.2M | −$68.3M | −$33.0M | −$22.1M | −$4.8M | −$1.1M |
| EBITDAderived | — | — | — | −$141.1M | −$65.5M | −$31.1M | −$21.0M | — | — |
| Net income | $204.8M | $89.2M | $10.9M | −$140.0M | −$69.6M | −$32.2M | −$19.1M | −$7.9M | −$1.1M |
| Basic EPSper diluted share | $7.08 | $3.12 | $0.40 | -$5.49 | -$3.13 | -$1.71 | -$1.20 | -$1.48 | -$1.31 |
| Diluted EPSper diluted share | $6.84 | $3.00 | $0.39 | -$5.49 | -$3.13 | -$1.71 | -$1.20 | -$1.48 | -$1.31 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 · 10b5-1 | Thomas John CharlesEVP, General Counsel | SellCommon Stock | 1.0K | $347.27 | $347.3K | 0 |
| Jun 4, 2026Form 4 · 10b5-1 | Krishnan SumaPresident, R&D | SellCommon Stock | 240 | $311.65 | $74.8K | 1.38M |
| Jun 4, 2026Form 4 · 10b5-1 | Krishnan SumaPresident, R&D | SellCommon Stock | 2.0K | $310.94 | $634.0K | 1.38M |
| Jun 4, 2026Form 4 · 10b5-1 | Krishnan SumaPresident, R&D | SellCommon Stock | 2.8K | $309.95 | $868.2K | 1.38M |
| Jun 4, 2026Form 4 · 10b5-1 | Krishnan SumaPresident, R&D | SellCommon Stock | 3.8K | $308.89 | $1.17M | 1.38M |